prIME Masterclass in Neuroendocrine Tumors

prIME Masterclass in Neuroendocrine Tumors

A Multidisciplinary Interactive Workshop

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Meeting Overview

Engage with experts in the field of neuroendocrine tumors (NETs) by joining this highly interactive 1.5-day live meeting. Our experts will provide a comprehensive update on the management of NETs, focusing on recent developments in imaging and therapeutic options by using the following strategies:

  • Didactic presentations
  • Interactive workshops
  • Case-based presentations and clinical management discussions
  • “Beat the Experts” NETs quiz
  • Q & A sessions

Date and Location

Friday & Saturday,
29 – 30 November 2019

Room: Ballroom
Hilton Budapest
Hess András tér 1-3
Budapest, Hungary



29 – 30 November 2019



Budapest, Hungary

Friday, 29 November—Day 1

10.30 Registration
12.00 Lunch
13.00 Welcome and introduction
Gyorgy Bodoky, MD, PhD; Dermot O’Toole, MD, FRCPI; and Philippe Ruszniewski, MD

SESSION I: Biology, Pathology, and Prognosis
Moderator: Dermot O’Toole, MD, FRCPI

13.15 Pathology workshop
Jean-Yves Scoazec, MD, PhD
13.45 Intracellular targeting of NETs
Justo Castaño, MS, PhD
14.15 Literature review: Basic science—what is new in 2019?
Chrissie Thirlwell, BSc, MD, PhD, FRCP
14.45 Challenges in NET management: How does the expert do it?
14.45 Small bowel resection
Reza Kianmanesh, MD, PhD
15.05 Follow-up: How long and how best?
Philippe Ruszniewski, MD
15.25 Metabolic complications of neuroendocrine neoplasia (NEN)
Wouter de Herder, MD, PhD
15.45 Screening and surveillance in multiple endocrine neoplasia type 1 (MEN 1)
Gerlof Valk, MD, PhD
16.05 Coffee break

SESSION II: Workshops
Four x 20-minute interactive workshops held in breakout rooms. Speakers will move to each of the four breakout rooms and repeat their workshops so that attendees may participate in every presentation.

  • Peptide receptor radionucleotide therapy (PRRT)
    Tessa Brabander, MD, PhD
  • Functional imaging for NETs
    Prakash Manoharan, MBChB, MRCP, FRCR
  • Interventional radiology
    Maxime Ronot, MD, PhD
  • Genomics in clinical decision making for NET management
    Eva Tiensuu Janson, MD, PhD
18.10 Evening break
20.00 Reception
20.15 Dinner

Saturday, 30 November—Day 2

08.00 Breakfast

SESSION III: Therapy and Patient Care
Moderators: Marianne Pavel, MD, and Philippe Ruszniewski, MD

08.45 Keynote lecture—Immunotherapy: Can we apply to NETs?
Wolf Fridman, MD, PhD
09.15 Q&A
09.45 Keynote lecture—Communicating risk and uncertainty in NETs
Lesley Fallowfield, DBE, FMedSci, Dphil, BSc
10.15 Literature review: Clinical—what is new in 2019?
Christos Toumpanakis, MD, PhD, FRCP, FEBGH, AGAF
10.45 Coffee break

SESSION IV: NET Fellows Forum
Moderators: Jaume Capdevila, MD, PhD; Dermot O’Toole, MD, FRCPI; and Marianne Pavel, MD
MDT Members: Reza Kianmanesh, MD, PhD; Maxime Ronot, MD, PhD; and Jean-Yves Scoazec, MD, PhD

11.15 Pancreatic NETs
Discussion led by: Marianne Pavel, MD
11.45 Rectal NETs
Discussion led by: Dermot O’Toole, MD, FRCPI
12.15 Pulmonary NETs
Discussion led by: Jaume Capdevila, MD, PhD
12.45 Lunch
13.45 “Beat the Experts” NETs quiz
Dermot O’Toole, MD, FRCPI, and Philippe Ruszniewski, MD
14.30 Current knowledge and future perspectives on NET treatment
Juan Valle, MBChB, MSc, FRCP
15.00 prIME Points™ and award ceremony
Gyorgy Bodoky, MD, PhD; Dermot O’Toole, MD, FRCPI; and Philippe Ruszniewski, MD
15.15 Afternoon coffee break and adjourn


  • Dermot O’Toole, MD, FRCPISt Vincent’s University Hospital
    St James's Hospital
    Trinity College Dublin
    Dublin, Ireland
  • Philippe Ruszniewski, MDUniversity of Paris VII
    Beaujon Hospital
    Paris, France
  • Local Host

  • György Bodoky, MD, PhDSt. László Hospital
    Budapest, Hungary
  • Faculty

  • Tessa Brabander, MD, PhDErasmus Medical Center
    Rotterdam, the Netherlands
  • Jaume Capdevila, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Justo Castaño, MS, PhDMaimonides Institute of Biomedical
    Investigation of Cordoba (IMIBIC)
    Cordoba, Spain
  • Lesley Fallowfield, DBE, FMedSci, Dphil, BScUniversity of Sussex
    Brighton, United Kingdom
  • Wolf Fridman, MD, PhDParis Descartes University
    Paris, France
  • Wouter de Herder, MD, PhDErasmus MC
    Rotterdam, the Netherlands
  • Reza Kianmanesh, MD, PhDR. Debré University Hospital
    Reims, France
  • Prakash Manoharan, MBChB, MRCP, FRCRThe Christie Neuroendocrine Centre of Excellence
    Manchester, United Kingdom
  • Marianne Pavel, MDUniversity Hospital Erlangen
    Erlangen, Germany
  • Maxime Ronot, MD, PhDBeaujon University Hospital
    Clichy, France
  • Jean-Yves Scoazec, MD, PhDGustave Roussy
    Villejuif, France
  • Chrissie Thirlwell, BSc, MD, PhD, FRCPUniversity College London
    The Royal Free Hospital
    London, United Kingdom
  • Eva Tiensuu Janson, MD, PhDUppsala University
    Uppsala, Sweden
  • Christos Toumpanakis, MD, PhD, FRCPThe Royal Free Hospital
    London, United Kingdom
  • Gerlof Valk, MD, PhDUMC Utrecht
    Utrecht, the Netherlands
  • Juan Valle, MBChB, MSc, FRCPThe Christie NHS Foundation Trust
    University of Manchester
    Manchester, United Kingdom

This educational activity is designed for European medical oncologists, endocrinologists, gastroenterologists, nuclear medicine specialists, and other healthcare providers involved and/or interested in the management of patients with NETs.

After successful completion of this educational activity, participants should be able to:

  • Describe the epidemiology, clinical characteristics, and natural history of NETs
  • Understand the cellular pathways of relevance in NETs and the role of molecular pathology in patient management
  • Select appropriate therapy from the increasing range of therapeutic options available for first and subsequent lines of treatment
  • Identify the potential for novel therapeutic strategies in the treatment of NETs

This educational activity is supported by Ipsen.

Continuing Education

prIME Masterclass in Neuroendocrine Tumors held in Budapest, Hungary on 29/11/2019-30/11/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 9 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 9.5 continuing professional development credits (CPD).


This activity is provided by prIME, a Medscape Oncology Company.


Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.